Dr. Grey AI

Cetrorelix (Cetrotide)

Peptide

Cetrorelix is a synthetic decapeptide GnRH antagonist. FDA-approved in 1999 for IVF/ICSI to prevent premature LH surge. Available as 0.25mg (multiple dose) and 3mg (single dose). Phase 3 trials show ~100% prevention of premature LH surge. Clinical pregnancy rate 26.3%. Nearly 100% prevention of ovarian hyperstimulation syndrome. Currently gold standard for IVF protocols.

Quick Answer

What it is

Cetrorelix is a synthetic decapeptide GnRH antagonist. FDA-approved in 1999 for IVF/ICSI to prevent premature LH surge.

Key findings

  • Grade A: LH Surge Prevention (Infertility)
  • Grade A: Clinical Pregnancy Rate (Infertility)
  • Grade A: OHSS Prevention (Infertility)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Cetrorelix (Cetrotide)

Quick Facts: Cetrorelix (Cetrotide)

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:10
  • Grade A Findings:4
  • Grade B Findings:2
  • Key Effect:Infertility
A4
B2
C2
D2
1 conditions · 10 outcomes

Detailed Outcomes

A
LH Surge Prevention
~100% prevention of premature LH surge across multiple RCTs. Single 3mg dose or daily 0.25mg both effective. Gold standard for IVF protocols.
large↓Improves
A
Clinical Pregnancy Rate
Phase 2/3 trials: 184 pregnancies from 732 patients (25.1%). Comparable to or better than GnRH agonist protocols.
moderate↑Improves
A
OHSS Prevention
Nearly 100% prevention of ovarian hyperstimulation syndrome. Major safety advantage over GnRH agonist protocols.
large↓Worsens
A
Follicle Development
Allows controlled ovarian stimulation without interference. Fewer injections required vs ganirelix in flexible protocols.
moderate↑Improves
B
Reproductive Outcomes
11 human trials support this finding. Human clinical trial data available.
moderate↑Improves
B
Anti-Cancer Activity
8 human trials support this finding. Human clinical trial data available.
moderate↑Improves
C
Hormone Levels
5 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Safety/Tolerability
3 human trials support this finding. Human clinical trial data available.
small↑Improves
D
Lipid Profile
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
D
Liver Protection
2 human trials support this finding. Human clinical trial data available.
small↑Improves

Research Citations (45)

Effectiveness and safety of GnRH antagonist originator and generic in real-world clinical practice: a retrospective cohort study.
(2024)
PMID: 38948522
Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds.
(2023)
PMID: 36630767
Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.
(2021)
PMID: 33548873
GnRH antagonist treatment of malignant adrenocortical tumors.
(2019)
PMID: 30400009
Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial.
(2018)
PMID: 29969209
Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial.
(2011)
PMID: 20810107
Cetrorelix suppresses the preovulatory LH surge and ovulation induced by ovulation-inducing factor (OIF) present in llama seminal plasma.
(2011)
PMID: 21624125
GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats.
(2010)
PMID: 20417958
A circadian egg timer gates ovulation.
(2010)
PMID: 20334830
Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study.
(2010)
PMID: 19339001